



Company Overview

Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Petaluma, California, with manufacturing operations in both the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences

Mar 4 2021, 5:03 PM EST

Sonoma Pharmaceuticals Reports Third Quarter FY 2021 Financial Results

Feb 16 2021, 5:30 PM EST

Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand

Jan 28 2021, 4:30 PM EST

Stock Overview

Symbol	SNOA
Exchange	Nasdaq
Market Cap	14.15m
Last Price	\$6.81
52-Week	\$3.55 - \$19.61

03/04/2021 04:00 PM EST

Investor Relations

T: 707-559-7380
ir@sonomapharma.com

Management Team

Amy Trombly

Interim Chief Executive Officer

Bruce Thornton

Chief Operating Officer

Jerry Dvonch

Chief Financial Officer

Sonoma Pharmaceuticals, Inc.

645 Molly Lane
Suite 150
Woodstock, GA 30189

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.